Phase 3 N=149 Alkali Therapy in Chronic Kidney Disease
Chronic Kidney Disease · Metabolic Acidosis
Primary: Sit to Stand to Sit Speed: Time Taken to Sit to Stand to Sit 10 Times — 23.8; 22.9 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Change in Gene Expression Th2/IL-13, "T22"/IL-22, S100A7 and S100A8, Th1/IFN-gamma, and Th17/IL-17A Jointly Correlated — -0.28 z-score
Phase 3 N=6,042 CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) — 20.7; 21.2 Events/ 1000 patients-years — p=<0.0001
Phase 2 N=32 Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
Primary Systemic Amyloidosis
Primary: Hematologic Response — 6; 3; 11; 5 Participants
N/A N=45 The Impact of Soft Contact Lens Attributes on Symptoms Associated With Digital Eye Strain in Symptomatic Soft Contact Lens Wearers
Asthenopia · Myopia
Primary: Subject Reported Eye Fatigue — 18; 21; 21; 17 units on a scale — p=0.18
N/A N=60 Performance Assessment of a Modified Daily Disposable Contact Lens
Refractive Errors · Myopia · Hyperopia
Primary: High Contrast Distance Visual Acuity (logMAR) — -0.04; -0.04; -0.05; -0.05 logMar
Phase 3 N=109 A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
HIV-1
Primary: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies/mL) (Virologic Response) at…
Phase 4 N=102 Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures
Laryngoscopic Surgical Procedures
Primary: Proportion of Patients Who Have a Clinically Acceptable Surgical Conditions — 0.89; 1 Proportion of patients
Phase 2 N=22 Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)
Infections, Bacterial
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Zero (Pre-dose) Over the Dosing Interval (AUC[0-tau]) of Gepotidacin — 20236.2; 29313.8 Hours* nanogram per…
Phase 2 N=176 Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Blood Stem Cell Transplant Failure · Leukemia · Hematologic Malignancies
Primary: Number of Participants With Non-relapse Mortality (NRM) — 8; 7; 2; 0 Participants
Phase 4 N=39 Gastric Acid Suppression and Probiotic Colonization
Probiotics
Primary: Relative Abundance of VSL#3 Probiotic Bacterial Strains When Ingested in the Presence or Absence of the Proton Pump Inhibitor (PPI) Omeprazole at Week 4. — 1.002; 0.8186…
Phase 2 N=196 A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus
Obesity and Diabetes Mellitus, Type 2
Primary: Percent Change From Baseline in Body Weight at Week 12 — -0.70; -5.25; -6.55; -7.92 Percent Change — p=<.001
Phase 3 N=38 A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation
Cystic Fibrosis
Primary: Change in Lung Clearance Index 2.5 (LCI2.5) — 0.20; -0.46 lung clearance index
Phase 2 N=40 Study to Compare Active Tymbion Iontophoresis to Sham Tymbion Iontophoresis for Anesthesia of the Tympanic Membrane
Healthy Volunteer
Primary: Subject-reported Visual Analog Scale (VAS) Pain Score Following Tympanic Membrane Tap for Subjects Treated With Active Tymbion Iontophoresis Compared to VAS Score for…
Phase 2 N=20 Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears
Rupture of Anterior Cruciate Ligament
Primary: Normative Isokinetic Knee Extension Strength, Measured in Newton Meters (Nm) at 26 Weeks Post-op — 0.881; 0.681 Nm — p=0.0498